Mark Denham’s Group Leader extension approved
Congratulations to Mark Denham, who has had his group leader contract extended until December 2019.
The Denham lab will continue their work with stem cells. They are interested in understanding the early pathogenic molecular events involved in Parkinson’s disease. To do this they use induced pluripotent stem cells derived from Parkinsonian patients to investigate genetic risk variances. In particular, they are investigating the link between patients with heterozygous GBA mutations and Parkinson’s disease.
The extension has the conditional option of obtaining a full extension for 2022.